GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors

Exclusion Criteria

• •Prior anti-cancer therapy that fulfills the following criteria: a total of more than six courses of an alkylating agent, a total of more than four courses of carboplatin-containing chemotherapy regimens, and a total of more than two courses of nitrosoureas or mitomycin C, high-dose chemotherapy requiring stem-cell support, and irradiation to \>= 25% of bone marrow-bearing areas
• •Current dyspnea at rest because of complications of advanced malignancy or other disease requiring continuous oxygen therapy
• •Known deficiency of dihydropyrimidine dehydrogenase (DPD)
• •Bisphosphonate therapy for symptomatic hypercalcemia
• •Known untreated or active central nervous system (CNS) metastases
• •Pregnancy, lactation, or breastfeeding
• •For Arm B:
• •Inadequately controlled hypertension
• •Prior history of hypertensive crisis or hypertensive encephalopathy
• •History of myocardial infarction or unstable angina within 6 months prior to the first dose of study treatment
• •History of stroke or transient ischemic attacks within 6 months prior to the first dose of study treatment
• •Significant vascular disease within 6 months prior to the first dose of study treatment
• •History of hemoptysis within 1 month prior to the first dose of study treatment
• •Patients with one or more pulmonary tumor masses with evidence of cavitation
• •Evidence of bleeding diathesis or significant coagulopathy
• •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of study treatment
• •History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to the first dose of study treatment
• •Clinical signs or symptoms of GI obstruction or requirement for parenteral hydration, parenteral nutrition, or tube feeding
• •Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
• •Serious, non-healing wound, active ulcer, or untreated bone fracture
• •The presence of an ulcerating breast cancer tumor will not render a patient ineligible
• •Proteinuria